Treatment of vascular dementia: The route of prevention

European Neurology

Volumn 60, Issue 5, 2008, Pages 217-223

  Sorrentino, G ^a,b,e   Migliaccio, R ^b,c   Bonavita, V ^b,d  

^a UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^b Istituto di Diagnosi e Cura 'Hermitage Capodimonte'   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e NONE   (Italy)

Author keywords

Alzheimer's disease; Diabetes; Hypercholesterolemia; Hyperhomocysteinemia; Hypertension; Mixed dementia; Prevention; Vascular dementia

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CHLORTALIDONE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRENDIPINE; PERINDOPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; TICLOPIDINE; WARFARIN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MORBIDITY; MULTIINFARCT DEMENTIA; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SUPPLEMENTATION; SYSTOLIC HYPERTENSION; VASCULAR DISEASE; WHITE MATTER;

CLINICAL TRIALS AS TOPIC; DEMENTIA, VASCULAR; DIABETES MELLITUS; DISEASE PROGRESSION; HUMANS; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; PRIMARY PREVENTION;

EID: 50249175050     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151696     Document Type: Review

References (60)

1. Henon H, Pasquier F, Durieu I, Godefroy O, Lucas C, Lebert F, Leys D: Preexisting dementia in stroke patients. Baseline frequency, associated factors, and outcome. Stroke 1997;28:2429-2436.
2. Victoroff J, Mack WJ, Lyness SA, Chui HC: Multicenter clinicopathological correlation in dementia. Am J Psychiatry 1995;152:1476-1484.
3. Staessen JA, Richart T, Birkenhäger WH: Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. Hypertension 2007;49:389-400.
4. De La Torre JC: Alzheimer's disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152-1162.
5. Hachinski VC, Bowler JV: Vascular dementia. Neurology 1993;43:2159-2160.
6. Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T: Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 2004;226:75-80.
7. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:85-151.
8. Qiu C, Winblad B, Fratiglioni L: The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487-499.
9. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H: Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31:780-786.
10. Launer LJ, Masaki K, Petrovich H, Foley D, Havlik RJ: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995;274:1846-1851.
11. Elias MF, D'Agostino RB, Elias PK, Wolf PA: Neuropsycological test performance, cognitive functioning, blood pressure, and age: the Framingham Heart Study. Exp Aging Res 1995;21:369-391.
12. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR, Atherosclerosis Risk in Community (ARIC) Study Investigators: Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001;56:42-48.
13. Swan GE, DeCarli C, Miller BL, Reed T, Wolf PA, Jack LM, Carmelli D: Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology 1998;51:986-993.
14. Tzourio C, Dufoil C, Ducimetriere P, Alperovicht A, for the EVA Study Group: Cognitive decline in individuals with high blood pressure. A longitudinal study in the elderly. Neurology 1999;53:1948-1952.
15. Di Bari M, Pahor M, Franse LV, Shorr RI, Wan JY, Ferrucci L, Somes GW, Applegate WB: Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. Am J Epidemiol 2001;153:72-78.
16. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764.
17. Thijs L, Staessen JA, Beleva S, Birkenhager WH, Bulpitt CJ, Celis H, Fletcher AE, Kermova R, Leonetti G, Laks T, Mantov S, Nachev C, Sarti C, Tuomilehto J, Fagard RH, on behalf of the Systolic Hypertension in Europe Investigators: How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2). Curr Control Trials Cardiovasc Med 2001;2:298-306.
18. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J, PROGRESS Collaborative Group: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069-1075.
19. Dufouil C, Chalmers J, Coskun O, Besancon V, Bousser MG, Guillon P, MacMahon S, Mazoyer B, Neal B, Woodward M, Tzourio-Mazoyer N, Tzourio C, PROGRESS MRI Substudy Investigators: Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke. The PROGRESS MRI substudy. Stroke 2005;112:1644-1650.
20. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
21. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-1762.
22. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-1653.
23. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
24. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E: Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) Study. The Care Investigators. Circulation 1999;99:216-223.
25. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
26. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group: Effect of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767.
27. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER Study Group, PROspective Study of Pravastatin in the Elderly at Risk: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630.
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT). JAMA 2002;288:2998-3007.
29. The Kyushu Lipid Intervention Study Group: Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb 2000;7:110-121.
30. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG: Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention: the Greek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220-228.
31. Amarenco P, Lavallée, Touboul PJ: Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004;3:271-278.
32. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
33. Rockwood K, Darvesh S: The risk of dementia in relation to statins and other lipid lowering agents. Neurol Res 2003;25:601-604.
34. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH: Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005;62:1047-1051.
35. Sorrentino G, Kanfer JN: Relationship between amyloid β peptide, cholesterol and statins. Recent Res Dev Biochem 2004;5:157-172.
36. Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443.
37. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000;356:1627-1631.
38. Naidu A, Xu Q, Catalano R, Cordell B: Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Res 2002;958:100-111.
39. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T: Simvastatin strongly reduces levels of Alzheimer's diseases beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-5861.
40. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-seceretase ADAM 10. Proc Natl Acad Sci USA 2001;98:5815-5820.
41. Pasquier F: Diabetes mellitus and dementia. Diabetes Metab 2006;32:403-414.
42. Mooradian AD: Central nervous system complication of diabetes mellitus: a prospective from the blood-brain barrier. Brain Res Brain Res Rev 1997;23:210-218.
43. Wong TY, Klein R, Sharrett AR, Nieto FJ, Boland LL, Couper DJ, Mosley TH, Kleim BE, Hubbard LD, Szklo M: Retinal microvascular abnormalities and cognitive impairment in middle-aged persons. The Atherosclerosis Risk in Communities Study. Stroke 2002;33:1487-1492.
44. Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H: The effect of improved glycaemic control on cognitive functions in the elderly patients with diabetes. J Gerontol 1993;48:117-121.
45. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-259.
46. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP: Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia and Alzheimer disease in Northern Ireland. Stroke 2002;33:2351-2356.
47. 12 in mild cognitive impairment, Alzheimer disease and vascular dementia. Am J Clin Nutr 2004;80:114-122.
48. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
49. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R: Plasma homocysteine levels and risk of Alzheimer's disease. Neurology 2004;62:1972-1976.
50. Snowdon DA, Tully CL, Smith CD, Riley KP, Markersbery WR: Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am J Clin Nutr 2000;71:993-998.
51. Ellinson M, Thomas J, Patterson A: A critical evaluation of the relationship between serum vitamin B, folate and total homocysteine with cognitive impairment in the elderly. J Hum Nutr Diet 2004;17:371-383.
52. 12 for cognition and dementia. Cochrane Database Syst Rev 2003;4:CD004514.
53. Gorelick PB: Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischaemic stroke pathogenesis and implications for therapy. Stroke 2002;33:862-875.
54. Collaborative overview of randomized trials of antiplatelet therapy. 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
55. Harbison JW: Ticlopidine versus aspirin for the prevention of recurrent stroke: analysis of patients with minor stroke from Ticlopidine Aspirin Stroke Study. Stroke 1992;23:1723-1727.
56. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339.
57. Sturmer T, Glynn RJ, Field TS, Taylor Jo, Hennekens CH: Aspirin use and cognitive function in the elderly. Am J Epidemiol 1996;143:683-691.
58. Richards M, Meade TW, Peart S, Brennan PJ, Mann AH: Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J Neurol Neurosurg Psychiatry 1997;62:269-272.
59. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lofti J: Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989;37:549-555.
60. Voko Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM: J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999;34:1181-1185.